openPR Logo
Press release

Asthma and COPD Drugs Market | Key Opportunities And Forecast 2024

10-03-2017 03:49 PM CET | Advertising, Media Consulting, Marketing Research

Press release from: Transparecny Market Research

/ PR Agency: Transparecny Market Research
Asthma and COPD Drugs Market | Key Opportunities And Forecast

The top five companies in the U.S. and China Asthma And Copd Drugs Market accounted for just under 64.0% in 2015, hinting at not just the consolidated nature of this industry but also at the immense competition among players. GlaxoSmithKline plc, Astrazeneca plc, Boehringer Ingelheim, Merck & Co. Inc., and Novartis AG currently enjoy the leading spots in the asthma and COPD drugs market.

According to Transparency Market Research, the opportunity in the U.S. and China asthma and COPD drugs market is slated to rise from a valuation of US$13.0 bn in 2015 to be worth US$18.7 bn by 2024. If these values hold true, the market is likely to expand at a modest CAGR of 4.1% therein.

China Poised to Witness Strong Growth by 2024

On the basis of drug class, the combination drugs segment is projected to account for a 55.4% share by 2024. This is attributed to the steadily rising preference for combination therapies as prescribed by doctors and the launch of new triple combination therapies during the forecast period. Expanding at the highest CAGR of 4.4% from 2016 to 2024, this segment offers immense scope for growth.

“Combination drugs are analyzed to be the most lucrative segment of the asthma and COPD drugs market, with a high attractiveness index. This is clearly evident from the increased sales of this class of drugs in 2015,” the author of the report states.

In terms of indication, asthma is projected to account for a higher share as compared to COPD during the forecast period. This is due to the increasing adoption of asthma drugs driven by higher diagnosis rates. Asthma is also evaluated to be the most lucrative segment of the asthma and COPD drugs market.

From a geographical standpoint, the U.S. is the dominant segment of the asthma and COPD drugs the market owing to greater awareness among patients and higher prices of these drugs. Although the country accounted for a whopping 81.4% share in 2015, it is estimated to lose market share by the end of the forecast period. On the other hand, China is poised to witness strong growth in the coming years, registering a 10.0% CAGR from 2016 to 2024.

Request to download and view full ToC -

http://www.transparencymarketresearch.com/report-toc/15857

Rising Incidence of Respiratory Diseases behind Growing Demand for COPD and Asthma Drugs

“One of the most prominent factors driving the asthma and COPD drugs market in the U.S. and China, and one that is likely to have a significant impact throughout the forecast period, is the growing prevalence of asthma and COPD in these two countries, especially in the last decade, the author of the study observes.

Statistics show that the prevalence of asthma across China is 1% to 2%, while it is well over 10% in some cities. Shanghai recorded a whopping 190% increase in the prevalence of asthma over the last decade. The U.S. has also seen an upsurge in asthma cases in the recent past. The Centers for Disease Control and Prevention (CDC) states that around one in 12 people in the U.S. are living with asthma, which translates to around 25 million people in the country.

Request to view Sample Report -

http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=15857

Another factor driving the market for asthma and COPD drugs in China and the U.S. is the growing usage of biologics in asthma, which is a relatively new method of treatment. Noteworthy advances have been made in the recent past, particularly for patients with severe disease symptoms. Ongoing developments by companies such as AstraZeneca and Roche are projected to provide a strong impetus to the asthma and COPD drugs market.

Contrary to this, patent expiry of blockbuster brands and frequent product recalls threaten to deter the growth of this market.

Asthma and COPD Drugs Market Report is available @ US$ 5795

http://www.transparencymarketresearch.com/checkout.php?rep_id=15857<ype=S

About Us

Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants, use proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

US Office Contact

90 State Street, Suite 700

Albany, NY 12207

Tel: +1-518-618-1030

USA – Canada Toll Free: 866-552-3453

Email: sales@transparencymarketresearch.com

Website: www.transparencymarketresearch.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Asthma and COPD Drugs Market | Key Opportunities And Forecast 2024 here

News-ID: 753111 • Views: 447

More Releases from Transparecny Market Research

Petroleum Jelly Market Export Research Report and Forecast to 2031
Negative Influence of COVID-19 Pandemic on Petroleum Jelly Market The COVID-19 pandemic has affected the petroleum jelly market to a considerable extent. The low demand from end-use industries led to a decline in the growth rate of the petroleum jelly market. Frequent lockdowns due to the emerging variants of the novel coronavirus caused disruptions in the production process. It also led to disturbances in the supply chain mechanisms. This aspect has
Lactic Acid & Polylactic Acid Market Historical Analysis and Industry Outlook 20 …
Reaching Sustainable Goals Delayed Due to COVID-19 Pandemic Although the COVID-19 outbreak has had a short-term positive impact on reducing greenhouse gas (GHG) emissions, it has delayed the timeline for reaching sustainable development goals. The adoption of sustainable production processes is linked to high costs. Such findings are anticipated to affect business activities in the lactic acid & polylactic acid market, since stakeholders are bullish on expanding uses of polylactic acid
Dehydrated Vegetables Market to Witness a Pronounce Growth at CAGR during 2018-2 …
Dehydrated Vegetables Market to Witness a Pronounce Growth at CAGR during 2018-2028 Food or vegetables dehydration or drying is a process that is used to eliminate moisture from food products and vegetables as it helps in preservation for long periods of time. Food dehydration is highly adopted as an ideal process to preserve seasonal fruits and vegetables. With easy storage, high nutritional value, and cost effectiveness, dehydrated vegetables have been witnessing
Succinic Acid Market Product Quality, Competitive Analysis and Opportunity Asses …
Succinic Acid Market: Introduction In terms of value, the global succinic acid market is anticipated to expand at a CAGR of ~7% from 2019 to 2027. Succinic acid is widely used in various industries such as pharmaceuticals, chemical, and food. Currently, major proportion of succinic acid is derived from petroleum feedstock Increase in construction and infrastructure development activity is expected to trigger the demand for resin, coating, and polyurethanes, which in

All 5 Releases


More Releases for COPD

COPD Therapeutics Global Market Research Report 2019
COPD Therapeutics Report by Material, Application, and Geography � Global Forecast to 2022 is a professional and in-depth research report on the world's major regional market conditions, focusing on the main regions (North America, Europe and Asia-Pacific) and the main countries (United States, Germany, united Kingdom, Japan, South Korea and China). Access more details about this report at: https://www.research2reports.com/report-medical-devices/copd-therapeutics-market/80858 The report firstly introduced the COPD Therapeutics basics: definitions, classifications, applications and market
Asthma and COPD Drugs Market worth $50,359 Million by 2022
"The key players of the Global COPD and asthma drugs market are employing novel concepts and ideas to improve, manage and control asthma & COPD, and also enhance their profitability so as to gain a competitive edge over the other market players. Seretide/Advair, Symbicort, and Singular were leading brands and accounted for around one-fourth share in world COPD and asthma drugs market." Global Asthma and COPD Drugs Market was valued at
Alarming Prevalence of COPD to Propel Oxygen Therapy Devices Market
"Oxygen therapy equipment market driven by increasing urbanization and rising levels of air pollution." An intelligence report on the global oxygen therapy equipment market has been added to the burgeoning portfolio of MarketResearchReports.biz. Titled, “Global Oxygen Therapy Equipment Market - Analysis By Product, Portability, Application, Region, Country: Opportunities and Forecast (2017- 2022) - By Product (Oxygen Concentrators, Liquid Oxygen Devices and Oxygen Cylinders), By Portability (Stationary, Portable Devices), By Application (COPD,
Global COPD and Asthma Devices Market Size
According to a new report, Global COPD and Asthma Devices Market, published by KBV Research, The Global COPD and Asthma Devices Market attained a market size of $ 27,465.1 Million in 2015 and is expected to reach $ 39,051.4 Million by 2022 growing at a CAGR of 5.2 % CAGR during 2016 – 2022. The Asia Pacific market dominated the Global COPD and Asthma Devices Market in 2015 and would
COPD Drug Market Opportunity & Clinical Pipeline Analysis
Close to 1 Billion people worldwide suffer from respiratory or pulmonary diseases. In the respiratory therapeutic domain, Asthma and COPD are the major categories, accounting for close to 75% of the total patient for respiratory or pulmonary diseases. Chronic obstructive pulmonary disease (COPD) is a disease which progresses in the lungs and requires treatment all through the life. It is an inflammatory disorder which is characterized by obstruction in the
Global COPD inhalers Industry:-Forecast 2022
Chronic Obstructive Pulmonary Disease (COPD) is a wide term used for progressive lung diseases which includes chronic bronchitis, emphysema, refractory asthma, and some forms of bronchiectasis. The symptoms of COPD includes recurrent coughing with or without sputum, difficulty in breathing, wheezing and tightness in the chest due to the blockage of lungs’ airways. More than 70 million people in the world are suffering from COPD as of 2015, majority of